Nicola Battelli

TL;DR: The activity of TAMs and associated molecules in TNBC are illustrated, focusing on their role in modulating the expression of PD-1/PD-L1 and on the emerging TAM-tailored strategies for TNBC patients.

TL;DR: It is suggested that pre-treatment NLR may be associated with DFS and OS patients with early TNBC, and further validation and a feasibility study are required before it can be considered for clinical use.

TL;DR: From the findings of this study, it is concluded that a subset of patients with a HER2-negative primary tumor presents Her2-positive CTCs during disease progression, although the HER2 shift rate seems to be lower than previously reported.

TL;DR: In this paper, the authors describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed death receptor 1(PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing their attention on the developing new immune agents and combination strategies with immune-checkpoint inhibitors.

TL;DR: There is an urgent need to develop novel diagnostic methods for initial detection and surveillance in both muscle invasive and muscle non-invasive bladder cancer, and there is growing evidence toward the use of minimally invasive “liquid biopsy” to identify biomarkers in urologic malignancy.